When No One Biomarker Predicts Enough
Farcast's TruSign technology comprehensively combines multi-modal assay data from every tumor processed with available multi-omics and clinical information
The AI (artificial intelligence) enabled technology computes response biosignatures of treatments with higher precision that truly elucidate the complexities of tumor responses
Application of such true human biosignatures through a clinical development program leads to a much more precise identification of responder phenotypes than traditional biomarkers
HISTOPATHOLOGY
Morphological assessment of mechanistic response of drug to assess proliferation, cell death and immune cell infiltration induced by treatment
GENE EXPRESSION
Measurement of differential gene expression resulting from therapeutic intervention
Patient cohort stratification discovery with baseline gene expression
(Opal690)%2C%20CD8(Opal570)%2C%20CD4(Opal520)%2C%20panCK(AF750)-image-6_j.jpeg)
Farcast proprietary images
PanCK
Fox P3
CD8
SPATIAL BIOLOGY
Live imaging that offers a comprehensive evaluation of true tumor microenvironment
Multiplex immunofluorescence techniques that help visualization of the spatial distribution of different sub-population of immune and cancer cells in the original human tumor microenvironment
Assessment of changes in spatial biology caused by therapeutic intervention in the treated tumor microenvironment
FLOWCYTOMETRY
Precise measurement and characterization of diverse immune cell populations within the tumor microenvironment
Customized panels for assessment of specific immune cell type activity indicative of therapy response
CYTOKINE PROFILING
Flexible, multiplexed quantitative evaluation of cytokines/chemokines released due to therapeutic intervention
Immune effector cells for assessing early response in tumor fragments in response to drug exposure
KINETIC ASSAYS
Discrete time course measurements to understand the metabolic state and viability of explants in the culture system for up to 72 hours
